Aerovate Therapeutics, Inc. (AVTE)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Aerovate Therapeutics, Inc. (AVTE)
Go deeper and ask any question about AVTE
Company Performance
Current Price
as of Sep 13, 2024$1.90
P/E Ratio
N/A
Market Cap
$54.85M
Description
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
Metrics
Overview
- HQWaltham, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerAVTE
- Price$1.9+1.06%
Trading Information
- Market Cap$54.85M
- Float67.83%
- Average Daily Volume (1m)199,519
- Average Daily Volume (3m)1,175,032
- EPS-$3.14
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$24.78M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$26.14M
- EV-$55.79M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account
Factset